Literature DB >> 14521318

Heparin resistance.

Jayaram Bharadwaj1, Chandrasekhar Jayaraman, Rakesh Shrivastava.   

Abstract

Heparin therapy is gaining more use in many clinical conditions. Considering the serious nature of the diseases managed with heparin, it is necessary to achieve the therapeutic goal within a short time to gain the best possible benefit. Adequate anticoagulation also is necessary during procedures such as cardiopulmonary bypass and hemodialysis. Heparin resistance, inability to achieve therapeutic anticoagulation, has been described in as many as 22% of patients undergoing open-heart surgeries. The results of undercoagulation can vary from subclinical coagulation to death. It also is necessary not to over anticoagulate a patient and to understand the existence of alternative methods for monitoring heparin therapy to prevent excess heparin therapy and its complications. Many common dinical situations can induce resistance to the action of heparin. Being aware of the existence of heparin resistance and taking timely appropriate action would prevent catastrophic consequences. The use of antithrombin III is one way of preventing heparin resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521318

Source DB:  PubMed          Journal:  Lab Hematol        ISSN: 1080-2924


  5 in total

1.  Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study.

Authors:  Jacob T Beyer; Kelly E Schoeppler; Giorgio Zanotti; Gregory M Weiss; Scott W Mueller; Robert MacLaren; Douglas N Fish; Tyree H Kiser
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-13       Impact factor: 2.389

Review 2.  [Heparin resistance and antithrombin deficiency].

Authors:  Norbert Maurin
Journal:  Med Klin (Munich)       Date:  2009-06-16

3.  Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study

Authors:  İlkay Anaklı; Perihan Ergin Özcan; Özlem Polat; Günseli Orhun; Gülçin Hilal Alay; Verda Tuna; Emre Çeliksoy; Mehmet Kılıç; Mutlu Mercan; Achmet Ali; Sevgi Beşışık; Figen Esen
Journal:  Turk J Haematol       Date:  2021-01-25       Impact factor: 1.831

4.  Management of heparin resistance due to antithrombin deficiency in a Chinese pregnant woman: a case report.

Authors:  Xiaoxin Zhang; Feng Guo; Qiaohong Wang; Wenxin Bai; Aimin Zhao
Journal:  J Int Med Res       Date:  2021-11       Impact factor: 1.671

5.  Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study.

Authors:  Lihua Zhang; Haitao Zhang; Jiong Zhang; Hong Tian; Ju Liang; Zhihong Liu
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.